Press Releases
- Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138
- Navitor’s Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression
- Navitor Expands Leadership Team with Appointment of James Randall Owen, M.D. as Chief Medical Officer